# SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

> **NCT03417895** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 59 (actual)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03417895
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-20
- **Primary completion:** 2021-08-04
- **Final completion:** 2021-08-04
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417895, "SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03417895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*